The Team

Professor Sabine Bahn
Professor Sabine Bahn
Professor Sabine Bahn - Chief Medical Officer
Co-founder of Psyomics Ltd
Sabine has dedicated more than 25 years to researching the molecular basis of mental illness, co-authoring more than 200 research papers on disorders including bipolar disorder and major depressive disorder, as well as previously launching the world’s first commercially available diagnostic aid for schizophrenia in conjunction with the NASDAQ-listed diagnostics company MyriadRBM Inc.
As co-founder of Psyomics Ltd, and head of the Cambridge Centre for Neuropsychiatric Research, Sabine is leading a team of scientists working on translating research breakthroughs into blood-based tests for bipolar disorder and major depression, as well incorporating evidence-based mental health research into the development of our digital tools. As a practising psychiatrist at the Peterborough and Cambridge NHS trust, Sabine has direct experience of the clinical need for new digital and biological tools for tackling some of the fundamental challenges in mental health.
Daniel Cowell
Daniel Cowell
Daniel Cowell - CEO
Co-founder of Psyomics Ltd
Daniel has spent the past 18 years leading the commercial, and scientific direction of various UK based biotechnology companies, in fields ranging from oncology to translational genomics research. He has previously co-founded the companies Pharmorphix, a drug discovery company which was subsequently acquired by Sigma Aldrich, and Hypoxium, a company providing custom cell biology research services for the development of novel oncology therapeutics which was then acquired by Horizon Discovery. As co-founder of Psyomics Ltd, Daniel is leading the commercial, strategic, clinical and scientific direction of the development of the company’s new digital tools, offering diagnosis and self-help solutions for mental health concerns.
Giles Barton-Owen
Giles Barton-Owen
Giles Barton-Owen
Chief Technology Officer
A computer science graduate from the University of Cambridge, Giles has worked as a freelance technology consultant for various organisations including the United Nations before joining Psyomics in 2016. As Chief Technology Officer, Giles leads and oversees all aspects of technology in the company, from research and development to the finalised products. His involvement ensures that all products are built to the highest standards of reliability and security while allowing the company to deliver innovation swiftly and efficiently.
Lauren Friend
Lauren Friend
Lauren Friend
Research and content lead
Lauren joined Psyomics in 2016 after completing a Natural Sciences degree at the University of Cambridge and a PhD in Neuropharmacology at University College London. As research and content lead at Psyomics, Lauren is responsible for identifying the latest and most relevant scientific research in the field of mental health, gathering opinion and guidance from service users, clinicians and experts, and integrating these findings to generate evidence-based questionnaires and content. This work is key to ensuring that Psyomics’ digital tools are of a scientific gold-standard and at the forefront of innovation in mental health technology.
Lynn Farrag
Lynn Farrag
Lynn Farrag
Clinical and regulatory project manager
Lynn has spent 35 years working as a project manager and head of clinical operations at a range of pharmaceutical and medical device manufacturing companies. Lynn has considerable experience in running clinical trials from Phase 1 to IV, as well as ensuring that company products meet regulatory and technical requirements to be registered for use in a clinical setting according to major EU and international directives. She is also a qualified ISO 13485 auditor.
Within Psyomics, Lynn is responsible for implementing measures to ensure immaculate clinical trial conduct and adherence with all regulatory aspects relating to medical devices in the development of the company’s digital and biological tools.
Sharmelee Thiahulan
Sharmelee Thiahulan
Sharmelee Thiahulan
Quality management systems
Sharmelee has two decades experience as a quality management consultant and regulatory professional in the pharmaceutical and medical device industries with a focus on diagnostic technologies. Sharmelee has experience in implementing and supporting quality management systems including ISO 9001, ISO 13485, CMDR SOR/98-282 and 21 CFR 820, as well as being a BSI qualified Lead ISO 13485 auditor, and a qualified PRINCE2 practitioner.
As part of the Psyomics team, Sharmelee’s experience will be integral to ensuring that all Psyomics products meet the latest medical device requirements according to the International Organisation for Standardization.
Emily Bell
Emily Bell
Emily Bell
Project lead for the Delta Trial app
Emily has 17 years of experience working as a freelance producer, managing creative projects and delivering content from the concept development stage to finalised products for a range of leading brands. At Psyomics, Emily is project lead for both Tresilio and the Delta Trial digital tools, where she is responsible for the delivery of the software platform including production partner selection, contracts, briefing, managing the Psyomics team workflow and ensuring clear communication between the research, commercial and regulatory teams.
Kalhari Palihakkara
Kalhari Palihakkara
Kalhari Palihakkara
Accountant
Kalhari has worked in the UK finance sector for more than 15 years, with five years experience as a senior accountant in an audit practice and four years as a finance manager in the biotechnology sector. She has been an associate member of the Chartered Institute of Management Accountants since 2008. At Psyomics, Kalhari’s experience as a finance manager is invaluable in producing timely, accurate financial information for the board, as well as preparing budgets and business plan forecasts to assist with year-end processes and statutory accounts preparation.

Service User Advisory Group

Service User Advisory Group
Service User Advisory Group
Service User Advisory Group
All aspects of our research and development are conducted in collaboration with a team of 10 individuals who have had first-hand experiences of existing mental health challenges within the healthcare system either as patients or carers. At Psyomics, we believe that the needs of patients and their families come first, and receiving the feedback and perspectives of this team - including concerns, suggestions for improvement, and recommendations - is invaluable to ensure that the tools we are developing are best suited to meet the needs of those they are intended to help.

Board and Advisors

Dr Neil Hunt
Dr Neil Hunt
Dr Neil Hunt
Advisor
Neil has been a consultant psychiatrist based in Cambridge for more than 20 years, and a member of the Royal College of Psychiatrists since 1987. He has co-authored numerous research papers in leading medical and psychiatric journals including the Lancet, over the past three decades, and is an author of two books including ‘Bipolar Disorder - Your Questions Answered.’ As a member of the Psyomics Advisory Board, Neil’s many years of clinical experience in treating patients with mental illnesses are invaluable in ensuring that our technologies address the needs of clinicians to aid them with early diagnosis, as well as ensuring that they provide patients with appropriate feedback and recommendations for self-help.
Dr Mark Agius
Dr Mark Agius
Dr Mark Agius
Advisor
Mark has worked as a practising psychiatrist for more than twenty years, having recently retired. He continues to be active in research in the field of mental health, publishing more than 100 research papers on bipolar disorder, early intervention in psychosis, unipolar depression and post-traumatic stress disorder. He is a visitor at the department of Psychiatry at the University of Cambridge, and a research associate of Clare College Cambridge. As a member of the Psyomics Advisory Board, Mark’s experience and knowledge, especially regarding the need for early intervention in mental illnesses, is vital to the development of our diagnostic technologies.
Dr Anne Dobree
Dr Anne Dobree
Dr Anne Dobree
Chair of the Board
Anne has 20 years of experience in helping university researchers commercialise their technology, and launch successful independent businesses based on their findings. Anne has been part of the University of Cambridge technology transfer team since 2001, holding a number of roles with Cambridge Enterprise including Head of Technology Transfer, and Head of Seed Funds. During her time with Cambridge Enterprise, Anne has supported numerous early stage companies, serving on the boards of Pneumacare, Cambridge CMOS Sensors, Aqdot, Cambridge Touch Technologies and others. She is also a founding member of Praxis, the UK Technology Transfer Training Programme. As Chair of the Psyomics Board, Anne brings considerable experience in turning research into successful commercial technologies, and delivering value to stakeholders.
David Blair
David Blair
David Blair
CFO
David has spent the past 25 years working with more than 50 high growth companies, helping them raise and successfully deploy in excess of £250m from public and private funds, and execute a variety of successful exits including merger, trade sale and IPO. David has also worked closely with financial providers, spending four years as Company Secretary of Prelude Trust plc, a main market listed Investment Trust, and since 2008 he has been CFO of Wyvern Fund, which invests in early stage technology companies. As Chief Financial Officer for Psyomics, David has proven experience in helping businesses build shareholder value, so entrepreneurs and investors alike can achieve their objectives. In addition, much of his previous work has seen him specialise in advising SMEs in the life science and technology arenas.
Barnaby Perks
Barnaby Perks
Barnaby Perks
Non Exec Director
Barnaby has been involved in building and growing digital health businesses for the past decade, currently serving as the CEO of Oxford VR, a University of Oxford spinout which uses virtual reality technology to deliver psychological interventions to patients. Barnaby also serves as the director of Tentsmuir Ltd, a company which provides practical support for digital health businesses, raising the funding required to turn innovative ideas into commercial success. As a non-executive director of Psyomics, Barnaby supports the company with its commercial strategy. His experience as founding CEO of Ieso Digital Health is particularly relevant to Psyomics future plans. Over the course of seven years, Barnaby built Ieso to become UK’s leading provider of live online cognitive behavioural therapy, obtaining multiple contracts with the NHS and Medicaid patients in the US, to deliver evidence-based mental health therapy services.
Martin Glen
Martin Glen
Martin Glen
Non Exec Director
Martin currently serves as an investment director for Parkwalk Advisors, and sits on the board of various portfolio companies, managing investments in UK university spinouts on behalf of EIS clients. Prior to that, he accumulated 25 years experience as a hedge fund manager and equities analyst, focusing on IPOs and follow-on deals. He has also been an Extel-rated analyst and an investment banker at various institutions including Lazard and Jeffries. As a non-executive director, Martin brings extensive experience to the Psyomics Board in terms of commercial and financial strategy.
Cambridge Innovation Centre, 23 Cambridge Science Park Milton Road, Cambridge, CB4 0EY
PsyOmics Ltd is registered in England and Wales (Registered number: 09470381)
Registered Office: Beech House, 4a Newmarket Road, Cambridge, CB5 8DT
VAT Registration No. 233 2946 14